News Headlines

  1. PPD Announces Industry-First Apprenticeship For Clinical Research Associates
    3/23/2017

    Pharmaceutical Product Development, LLC (PPD) recently announced its launch of a clinical research associates (CRAs) apprenticeship program targeted to military veterans and military service members with medical backgrounds who are transitioning to the civilian workforce. 

  2. Medidata’s Clinical Technology Platform Selected For Groundbreaking ‘Beat AML Master Trial’
    3/23/2017

    Medidata, the leading global provider of cloud-based technology and data analytics for clinical research, recently announced that The Leukemia & Lymphoma Society (LLS) has selected the Medidata Clinical Cloud to power its novel trial for acute myeloid leukemia (AML).

  3. Stemline Therapeutics Announces Completion Of Enrollment In Stage 3 Of The SL-401 Pivotal Trial In BPDCN
    3/23/2017

    Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that enrollment of Stage 3 in the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been completed.

  4. Thermo Fisher Scientific And The Cell And Gene Therapy Catapult Collaborate To Optimise Advanced Therapy Supply Chain
    3/21/2017

    To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific, the world leader in serving science, recently announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to provide developers with both the manufacturing capability and distribution, logistics, and storage capacity needed to create a seamless supply chain to accelerate cell and gene therapy development and commercialsation.

  5. RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease
    3/21/2017

    RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced dosing of the first patient in the open-label extension study to the Phase III study with RHB-104 for the treatment of Crohn’s Disease (the MAP US study).

  6. Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102
    3/21/2017

    Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, recently announces that it has successfully completed its phase 1 trial with MIN-102.

  7. PCI Clinical Services Announces Additional Cryogenic Storage Capacity At Its Rockford, IL Site
    3/21/2017

    Leading pharmaceutical outsourcing services provider PCI Clinical Services (PCI) has announced a second phase 400 percent increase in Cyrogenic storage capabilities at its Rockford, Illinois site.

  8. Neothetics Announces Last Subject Enrolled In Phase 2 Proof Of Concept Trial For LIPO-202 For The Reduction Of Submental Subcutaneous Fat
    3/20/2017

    Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.

  9. DrugDev Dominates Clinical Site Payments With Record Milestone Of Over $2B Processed To Sites On Behalf Of Sponsors And CROs Worldwide
    3/20/2017

    Sponsors and CROs worldwide have elevated DrugDev to an industry milestone of over $2B in aggregate payments to clinical investigator sites – an accomplishment unequaled by any other provider, including all but the very largest CROs.

  10. Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint Of Progression-Free Survival
    3/20/2017

    Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS).